Actinium Pharmaceuticals Inc. (ATNM) 6.32 $ATNM
Actinium to Present at the 21st Annual BioCentury NewsMakers Conference on Friday, September 26th
Marketwire - Tue Sep 16, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium will present at the 21st Annual BioCentury NewsMakers Conference on Friday, September 26, 2014 at 10:00 a.m. (EDT) at the Millennium Broadway Hotel & Conference Center in New York.
MD Anderson Department Chair Richard E. Champlin, M.D. Joins Actinium's Iomab(TM)-B Scientific Advisory Board
Business Wire - Wed Sep 10, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of Richard E. Champlin, M.D. of MD Anderson Cancer Center to its Scientific Advisory Board (SAB) for Iomab(TM)-B, the Company's lead radioimmunotherapy asset which is preparing to enter a Phase III pivotal trial. MD Anderson is one of the world's most respected centers devoted exclusively to patient care, research, education and prevention. For 10 of the past 12 years, MD Anderson has ranked No. 1 in cancer care in the "Best Hospitals" survey published by U.S. News & World Report.
Actinium Files Orphan Drug Application for Use of Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
Business Wire - Wed Sep 03, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for Actimab-A, a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase 1/2 clinical trial. The Company expects to provide interim results for the Actimab-A trial around the same time as the American Society of Hematology (ASH) meeting in December 2014.
Actinium to Present at the Rodman & Renshaw Annual Global Investment Conference on September 10th
Business Wire - Thu Aug 28, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium will present at the Rodman & Renshaw Annual Global Investment Conference sponsored by H.C. Wainwright & Co., LLC., on Wednesday, September 10th, at 1:40 PM ET, at the New York Palace Hotel.
Global Hodgkins Lymphoma Therapeutics Market 2014-2018: Bristol Myers Squibb, F. Hoffmann-La Roche, Merck & Co & Pfizer Dominate the Industry
M2 - Fri Aug 22, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g8ls35/global_hodgkins) has announced the addition of the "Global Hodgkins Lymphoma Therapeutics Market 2014-2018" report to their offering. The Global Hodgkin's Lymphoma Therapeutics market will grow at a CAGR of 6.84 percent over the period 2013-2018. There has been an increase in awareness of Hodgkin's lymphoma among patients and physicians. Enhanced patient and physician awareness is expected to lead to earlier disease diagnosis and treatment. The acceptability of Hodgkin's lymphoma drugs is expected to rise because of the increasing public awareness. Raising general awareness about Hodgkin's lymphoma has led to an increase in research funding and support for clinical and support services. For instance, September 15 is celebrated as WLAD by the LRF. The program was initiated to make people more aware about both Hodgkin's lymphoma and NHL in terms of symptom recognition, early diagnosis, and treatment According to the report the Global Hodgkin's Lymphoma Therapeutics market is driven by several factors. One of the main drivers in this market is the improved diagnostic techniques. Improved diagnostic techniques have led to the treatment of Hodgkin's lymphoma in an aggressive way and have driven revenue growth in a positive direction. Improvement in the diagnosis leads to the early detection and treatment of the disease. Further, the report states that the Global Hodgkin's Lymphoma Therapeutics market is inhibited by some serious challenges. One of the main challenges is the high cost of Hodgkin's lymphoma treatment. Despite the numerous benefits, the high cost of treatment options hinders the acceptability among patients. Many patients do not have the required budget for investing in high-cost treatment options. The Global Hodgkin's Lymphoma Therapeutics market can be divided into eight segments: - Alkylating Antineoplastic Agents - Antibiotic Antineoplastic Agents - Antineoplastics Vinca Alkaloid Agents - Podophyllotoxin Derivative Antineoplastic Agents - Antimetabolite Antineoplastic Agents - Anthracycline Antineoplastic Agents - Antimicrotubular Antineoplastics - Corticosteroids Key Vendors - Bristol Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Merck & Co. Inc. - Pfizer Inc. Other Prominent Vendors - 4SC AG - Actinium Pharmaceuticals Inc. - Aeterna Zentaris Inc. - Affimed Therapeutics AG - Hospira Inc. - Incyte Corp. - Novartis AG - Philogen S.p.A. - Seattle Genetics Inc. - Sigma-Tau Pharmaceuticals Inc. - Stemline Therapeutics Inc. - Teva Pharmaceutical Industries Ltd. For more information visit http://www.researchandmarkets.com/research/g8...l_hodgkins
Actinium to Present at the Canaccord Genuity 34th Annual Growth Conference on August 13th
Business Wire - Tue Aug 05, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium, will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014, at 9:30 a.m. ET in Boston, MA.
Actinium Pharmaceuticals Provides Mid-Year Update Directed at Existing and Future Shareholders
Business Wire - Mon Aug 04, 7:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today provided a Mid-Year Corporate Update to new and existing shareholders. The highlights below underscore the significant progress that the Company has achieved on all material fronts this year which leave it well positioned to execute on its business plan and capitalize on the near-term promise of its core product candidates Iomab(TM)-B and Actimab-A.
Baylor Sammons Cancer Center Joins as Clinical Trial Site for Actinium's Actimab-A Clinical Trial
Business Wire - Wed Jul 30, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A. The center joins several other clinical trial sites currently participating in the Actimab-A Phase I/II trial to potentially address the rapid mortality and unmet medical need for older patients with newly diagnosed acute myeloid leukemia (AML).
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Jul 24, 9:49AM CDT
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"
TM) television program will feature two emerging growth companies on Fox Business nationwide on Thursday, July 24, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, July 26, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, July 27, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday July 27, 2014 at 3:30 p.m. HKT.
CORRECTING and REPLACING Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program
Business Wire - Wed Jul 16, 9:54AM CDT
Headline of release should read: Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program (instead of Actinium Pharmaceuticals, Inc. Announces Launch of Additional Antibody Actinium-225 Labeling Program). Subhead of release should read: Development Of Actinium 225 Labeled Antibody Targeted at Selected Hematologic Malignancies (instead of Actinium Pharmaceuticals Initiates Development Of Actinium 225 Labeled Antibody For Hematologic Malignancies). Also, a sentence was added to the end of the first paragraph.
Actinium Pharmaceuticals, Inc. Announces Launch of Additional Antibody Actinium-225 Labeling Program
Business Wire - Wed Jul 16, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers initiated development of an additional antibody construct labeled with actinium-225. The antibody has potential to be used in treatment of a number of blood cancers. Preclinical work for this additional antibody will be done at Memorial Sloan Kettering Cancer Center. A significant amount of both clinical and preclinical data for the antibody labeled with other payloads is available from numerous clinical trials in a number of indications.
Actinium reports exercise of additional 157,123 shares in underwriters' option, with stronger balance sheet to support late-stage pipeline development
M2 - Fri Jul 11, 5:40AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) disclosed on Thursday that the underwriters of its public offering have exercised their over-allotment option to purchase an additional 157,123 shares.
Actinium Announces Exercise of Greenshoe Option
Business Wire - Thu Jul 10, 3:10PM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the underwriters of the previously announced offering of 1,670,000 common shares of Actinium exercised their over-allotment option to purchase an additional 157,123 shares from the Company for $7.50 per share. The public offering previously closed on June 30, 2014.
Baylor Oncology Medical Director Joins Actinium's Iomab-B Scientific Advisory Board
Business Wire - Mon Jul 07, 4:10PM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of M. Yair Levy, MD of Baylor to its Scientific Advisory Board (SAB) for Iomab(TM)-B. Iomab(TM)-B, the Company's lead radioimmunotherapy asset, is entering a Phase 3 trial to potentially address the rapid mortality and significant unmet medical need for older patients with acute myeloid leukemia (AML) and well as in other cancer indications.
Actinium Joins Russell 3000(R), Russell 2000(R), Russell Global, and Russell Micro-Cap(R) Indexes
Business Wire - Tue Jul 01, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, joined the broad-market Russell 3000(R) Index as well as the Russell 2000(R) , Russell Global and Russell Microcap(R) on June 27, 2014.
Actinium concludes public offering at USD7.50 per share
M2 - Tue Jul 01, 3:18AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) reported on Monday the completion of its public offering of 1,670,000 common shares at USD7.50 per share.
Actinium Closes Public Offering of Common Shares
Business Wire - Mon Jun 30, 10:28AM CDT
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company" (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the closing of its previously announced public offering of 1,670,000 shares of its common stock at a price to the public of $7.50 per share. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 250,500 shares of common stock solely to cover over-allotments, if any.
Preeminent Oncology Clinicians from Leading Cancer Centers Join Actinum's Newly Established Iomab-B Scientific Advisory Board
Business Wire - Thu Jun 26, 8:22AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the establishment of its Scientific Advisory Board (SAB) for Iomab(TM)-B comprised of several preeminent clinicians in the fields of oncology, hematology, and bone marrow transplant. Combining the wealth of clinical, strategic, and scientific experience in cancer drug development, the Scientific Advisory Board is well suited to support the company's development strategy for the advancement of Iomab(TM)-B, the Company's lead radioimmunotherapy asset, in a Phase 3 trial to potentially address the significant unmet medical need for older patients with acute myeloid leukemia (AML) and well as in other cancer indications.
Actinium prices public offering at USD7.50 per share
M2 - Thu Jun 26, 5:09AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) reported on Wednesday that it has priced a public offering of 1,670,000 common shares at USD7.50 per share.
Actinium to Present at the 21st Annual BioCentury NewsMakers Conference on Friday, September 26th
Marketwire - Tue Sep 16, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium will present at the 21st Annual BioCentury NewsMakers Conference on Friday, September 26, 2014 at 10:00 a.m. (EDT) at the Millennium Broadway Hotel & Conference Center in New York. MD Anderson Department Chair Richard E. Champlin, M.D. Joins Actinium's Iomab(TM)-B Scientific Advisory Board
Business Wire - Wed Sep 10, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of Richard E. Champlin, M.D. of MD Anderson Cancer Center to its Scientific Advisory Board (SAB) for Iomab(TM)-B, the Company's lead radioimmunotherapy asset which is preparing to enter a Phase III pivotal trial. MD Anderson is one of the world's most respected centers devoted exclusively to patient care, research, education and prevention. For 10 of the past 12 years, MD Anderson has ranked No. 1 in cancer care in the "Best Hospitals" survey published by U.S. News & World Report. Actinium Files Orphan Drug Application for Use of Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
Business Wire - Wed Sep 03, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for Actimab-A, a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase 1/2 clinical trial. The Company expects to provide interim results for the Actimab-A trial around the same time as the American Society of Hematology (ASH) meeting in December 2014. Actinium to Present at the Rodman & Renshaw Annual Global Investment Conference on September 10th
Business Wire - Thu Aug 28, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium will present at the Rodman & Renshaw Annual Global Investment Conference sponsored by H.C. Wainwright & Co., LLC., on Wednesday, September 10th, at 1:40 PM ET, at the New York Palace Hotel. Global Hodgkins Lymphoma Therapeutics Market 2014-2018: Bristol Myers Squibb, F. Hoffmann-La Roche, Merck & Co & Pfizer Dominate the Industry
M2 - Fri Aug 22, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g8ls35/global_hodgkins) has announced the addition of the "Global Hodgkins Lymphoma Therapeutics Market 2014-2018" report to their offering. The Global Hodgkin's Lymphoma Therapeutics market will grow at a CAGR of 6.84 percent over the period 2013-2018. There has been an increase in awareness of Hodgkin's lymphoma among patients and physicians. Enhanced patient and physician awareness is expected to lead to earlier disease diagnosis and treatment. The acceptability of Hodgkin's lymphoma drugs is expected to rise because of the increasing public awareness. Raising general awareness about Hodgkin's lymphoma has led to an increase in research funding and support for clinical and support services. For instance, September 15 is celebrated as WLAD by the LRF. The program was initiated to make people more aware about both Hodgkin's lymphoma and NHL in terms of symptom recognition, early diagnosis, and treatment According to the report the Global Hodgkin's Lymphoma Therapeutics market is driven by several factors. One of the main drivers in this market is the improved diagnostic techniques. Improved diagnostic techniques have led to the treatment of Hodgkin's lymphoma in an aggressive way and have driven revenue growth in a positive direction. Improvement in the diagnosis leads to the early detection and treatment of the disease. Further, the report states that the Global Hodgkin's Lymphoma Therapeutics market is inhibited by some serious challenges. One of the main challenges is the high cost of Hodgkin's lymphoma treatment. Despite the numerous benefits, the high cost of treatment options hinders the acceptability among patients. Many patients do not have the required budget for investing in high-cost treatment options. The Global Hodgkin's Lymphoma Therapeutics market can be divided into eight segments: - Alkylating Antineoplastic Agents - Antibiotic Antineoplastic Agents - Antineoplastics Vinca Alkaloid Agents - Podophyllotoxin Derivative Antineoplastic Agents - Antimetabolite Antineoplastic Agents - Anthracycline Antineoplastic Agents - Antimicrotubular Antineoplastics - Corticosteroids Key Vendors - Bristol Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Merck & Co. Inc. - Pfizer Inc. Other Prominent Vendors - 4SC AG - Actinium Pharmaceuticals Inc. - Aeterna Zentaris Inc. - Affimed Therapeutics AG - Hospira Inc. - Incyte Corp. - Novartis AG - Philogen S.p.A. - Seattle Genetics Inc. - Sigma-Tau Pharmaceuticals Inc. - Stemline Therapeutics Inc. - Teva Pharmaceutical Industries Ltd. For more information visit http://www.researchandmarkets.com/research/g8...l_hodgkins
Actinium to Present at the Canaccord Genuity 34th Annual Growth Conference on August 13th
Business Wire - Tue Aug 05, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium, will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014, at 9:30 a.m. ET in Boston, MA. Actinium Pharmaceuticals Provides Mid-Year Update Directed at Existing and Future Shareholders
Business Wire - Mon Aug 04, 7:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today provided a Mid-Year Corporate Update to new and existing shareholders. The highlights below underscore the significant progress that the Company has achieved on all material fronts this year which leave it well positioned to execute on its business plan and capitalize on the near-term promise of its core product candidates Iomab(TM)-B and Actimab-A. Baylor Sammons Cancer Center Joins as Clinical Trial Site for Actinium's Actimab-A Clinical Trial
Business Wire - Wed Jul 30, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A. The center joins several other clinical trial sites currently participating in the Actimab-A Phase I/II trial to potentially address the rapid mortality and unmet medical need for older patients with newly diagnosed acute myeloid leukemia (AML). RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Jul 24, 9:49AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature two emerging growth companies on Fox Business nationwide on Thursday, July 24, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, July 26, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, July 27, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday July 27, 2014 at 3:30 p.m. HKT. CORRECTING and REPLACING Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program
Business Wire - Wed Jul 16, 9:54AM CDT
Headline of release should read: Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program (instead of Actinium Pharmaceuticals, Inc. Announces Launch of Additional Antibody Actinium-225 Labeling Program). Subhead of release should read: Development Of Actinium 225 Labeled Antibody Targeted at Selected Hematologic Malignancies (instead of Actinium Pharmaceuticals Initiates Development Of Actinium 225 Labeled Antibody For Hematologic Malignancies). Also, a sentence was added to the end of the first paragraph.
Actinium Pharmaceuticals, Inc. Announces Launch of Additional Antibody Actinium-225 Labeling Program
Business Wire - Wed Jul 16, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers initiated development of an additional antibody construct labeled with actinium-225. The antibody has potential to be used in treatment of a number of blood cancers. Preclinical work for this additional antibody will be done at Memorial Sloan Kettering Cancer Center. A significant amount of both clinical and preclinical data for the antibody labeled with other payloads is available from numerous clinical trials in a number of indications. Actinium reports exercise of additional 157,123 shares in underwriters' option, with stronger balance sheet to support late-stage pipeline development
M2 - Fri Jul 11, 5:40AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) disclosed on Thursday that the underwriters of its public offering have exercised their over-allotment option to purchase an additional 157,123 shares.
Actinium Announces Exercise of Greenshoe Option
Business Wire - Thu Jul 10, 3:10PM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the underwriters of the previously announced offering of 1,670,000 common shares of Actinium exercised their over-allotment option to purchase an additional 157,123 shares from the Company for $7.50 per share. The public offering previously closed on June 30, 2014. Baylor Oncology Medical Director Joins Actinium's Iomab-B Scientific Advisory Board
Business Wire - Mon Jul 07, 4:10PM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of M. Yair Levy, MD of Baylor to its Scientific Advisory Board (SAB) for Iomab(TM)-B. Iomab(TM)-B, the Company's lead radioimmunotherapy asset, is entering a Phase 3 trial to potentially address the rapid mortality and significant unmet medical need for older patients with acute myeloid leukemia (AML) and well as in other cancer indications. Actinium Joins Russell 3000(R), Russell 2000(R), Russell Global, and Russell Micro-Cap(R) Indexes
Business Wire - Tue Jul 01, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, joined the broad-market Russell 3000(R) Index as well as the Russell 2000(R) , Russell Global and Russell Microcap(R) on June 27, 2014. Actinium concludes public offering at USD7.50 per share
M2 - Tue Jul 01, 3:18AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) reported on Monday the completion of its public offering of 1,670,000 common shares at USD7.50 per share.
Actinium Closes Public Offering of Common Shares
Business Wire - Mon Jun 30, 10:28AM CDT
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"
(NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the closing of its previously announced public offering of 1,670,000 shares of its common stock at a price to the public of $7.50 per share. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 250,500 shares of common stock solely to cover over-allotments, if any. Preeminent Oncology Clinicians from Leading Cancer Centers Join Actinum's Newly Established Iomab-B Scientific Advisory Board
Business Wire - Thu Jun 26, 8:22AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the establishment of its Scientific Advisory Board (SAB) for Iomab(TM)-B comprised of several preeminent clinicians in the fields of oncology, hematology, and bone marrow transplant. Combining the wealth of clinical, strategic, and scientific experience in cancer drug development, the Scientific Advisory Board is well suited to support the company's development strategy for the advancement of Iomab(TM)-B, the Company's lead radioimmunotherapy asset, in a Phase 3 trial to potentially address the significant unmet medical need for older patients with acute myeloid leukemia (AML) and well as in other cancer indications. Actinium prices public offering at USD7.50 per share
M2 - Thu Jun 26, 5:09AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) reported on Wednesday that it has priced a public offering of 1,670,000 common shares at USD7.50 per share.
